Plain-English translation of NCT04896606 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new approach called SARS-CoV-2-specific cytotoxic T lymphocytes (immune cells trained to fight the COVID-19 virus) to treat people hospitalized with mild to moderate COVID-19. The immune cells come from a family member who has already recovered from COVID-19 and are carefully matched to your genetic type. Researchers believe these cells may help your body fight off the virus more effectively.
Right now, there are no proven standard treatments specifically approved by the FDA for COVID-19. This treatment explores whether using trained immune cells from a recovered family member could be a safe and effective way to help patients recover, especially those with underlying health conditions that put them at higher risk.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to one of two groups: one group receives the new immune cell treatment up to 5 times over about 10 weeks (along with standard COVID-19 care), while the other group receives standard care alone. You will be hospitalized during this time and have regular blood tests and health check-ups to monitor how you respond to the treatment and to watch for any side effects.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States